3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Pleural Effusion, Malignant
3
Immunoglobulin Light-chain Amyloidosis
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Mycosis Fungoides
2
Lymphoma, Non-Hodgkin
2
Amyloidosis
2
Waldenstrom Macroglobulinemia
1
Urologic Neoplasms
1
Tuberous Sclerosis
1
Tissue Adhesions
1
Skin Toxicity
1
Sezary Syndrome
1
Ras-wildtype Colorectal Cancer
1
Polyps
1
Polycystic Ovary Syndrome
1
Pleural Neoplasms
1
Pancreatic Neoplasms
1
Pain
1
Neurofibromatosis 2
1
Neoplasms, Second Primary
1
Myoma
1
Menstruation Disturbances
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Interventions
Cyclophosphamide
41
Peripheral Blood Stem Cell Transplantation
40
fludarabine phosphate
36
Whole-Body Irradiation
27
Mycophenolic Acid
27
Tacrolimus
23
Busulfan
23
Cyclosporine
22
Antilymphocyte Serum
20
Etoposide
17
Methotrexate
16
Filgrastim
16
Melphalan
14
romidepsin
13
Radiotherapy
13
Flow Cytometry
12
Methylprednisolone
10
Brentuximab Vedotin
10
Therapeutics
9
Psychiatric Rehabilitation
9
Lenalidomide
8
pembrolizumab
7
fludarabine
7
Sirolimus
7
Rituximab
7
Bortezomib
7
Bexarotene
7
mogamulizumab
6
Polymerase Chain Reaction
6
Gemcitabine
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma, T-Cell, Cutaneous
×
Doxycycline
×
Clear all
NCT02341209
2021-04-27
CTCL
Rochester General Hospital
Phase 2
Terminated
1 enrolled